In the last trading session, 1.31 million Twist Bioscience Corp (NASDAQ:TWST) shares changed hands as the company’s beta touched 2.39. With the company’s per share price at $35.18 changed hands at -$1.81 or -4.89% during last session, the market valuation stood at $2.10B. TWST’s last price was a discount, traded about -73.11% off its 52-week high of $60.90. The share price had its 52-week low at $27.41, which suggests the last value was 22.09% up since then. When we look at Twist Bioscience Corp’s average trading volume, we note the 10-day average is 1.36 million shares, with the 3-month average coming to 1.06 million.
Analysts gave the Twist Bioscience Corp (TWST) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.77. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended TWST as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Twist Bioscience Corp’s EPS for the current quarter is expected to be -0.57.
Twist Bioscience Corp (NASDAQ:TWST) trade information
Instantly TWST was in red as seen at the end of in last trading. With action -9.66%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -24.30%, with the 5-day performance at -9.66% in the red. However, in the 30-day time frame, Twist Bioscience Corp (NASDAQ:TWST) is -4.17% down. Looking at the short shares, we see there were 8.83 million shares sold at short interest cover period of 7.21 days.
The consensus price target for the stock as assigned by Wall Street analysts is 54, meaning bulls need an upside of 34.85% from its current market value. According to analyst projections, TWST’s forecast low is 50 with 58 as the target high. To hit the forecast high, the stock’s price needs a -64.87% plunge from its current level, while the stock would need to soar -42.13% for it to hit the projected low.
Twist Bioscience Corp (TWST) estimates and forecasts
Year-over-year growth is forecast to reach 20.08% up from the last financial year.
Consensus estimates given by 10 financial analysts project the company’s revenue in the current quarter to hit an average of 91.95M. 9 analysts are of the opinion that Twist Bioscience Corp’s revenue for the current quarter will be 95.56M. The company’s revenue for the corresponding quarters a year ago was 75.3M and 81.46M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 22.11%. The estimates for the next quarter sales put growth at 17.31%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 1.70%. The 2025 estimates are for Twist Bioscience Corp earnings to increase by 43.47%, but the outlook for the next 5-year period is at 37.54% per year.
TWST Dividends
Twist Bioscience Corp is expected to release its next quarterly earnings report on 2025-Feb-02.
Twist Bioscience Corp (NASDAQ:TWST)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.14% of Twist Bioscience Corp shares while 112.33% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 114.79%. There are 112.33% institutions holding the Twist Bioscience Corp stock share, with ARK INVESTMENT MANAGEMENT LLC the top institutional holder. As of 2024-06-30, the company held 10.5415% of the shares, roughly 6.13 million TWST shares worth $302.06 million.
ARTISAN PARTNERS LIMITED PARTNERSHIP holds the second largest percentage of outstanding shares, with 10.4371% or 6.07 million shares worth $299.06 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were ARK ETF Trust-ARK Innovation ETF and ARK ETF Trust-ARK Genomic Revolution ETF . With 3.54 shares estimated at $124.45 million under it, the former controlled 5.93% of total outstanding shares. On the other hand, ARK ETF Trust-ARK Genomic Revolution ETF held about 3.78% of the shares, roughly 2.26 shares worth around $79.39 million.
